AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy
AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy
复制标题
AKR1B10表达预测胃癌对新辅助化疗的反应
DOI：
10.3892/ol.2018.9705
复制
发表时间：
2019-01-01
期刊：
影响因子：
2.9
通讯作者：
Tang, Xiuwen
中科院分区：
文献类型：
--
作者：
Ahmed, Syed Minhaj Uddin;Jiang, Zi Nong;Tang, Xiuwen
需要有效的方法来预测肿瘤对术前化疗的反应。醛酮还原酶家族1成员B10（AKR 1B 10）主要在胃肠道中表达，并在癌症发展和进展中发挥重要作用。本研究探讨AKR 1B 10表达是否可以预测局部进展期胃癌的治疗反应。2006年1月至2015年12月期间，共有53例胃癌患者接受了新辅助化疗，随后进行了手术。采用免疫组化法检测石蜡包埋活检标本中AKR 1B 10的蛋白表达水平。Western blotting证实AKR 1B 10蛋白主要定位于细胞质。采用χ2和Fisher精确检验确定AKR 1B 10与许多临床病理特征的相关性。单因素和多因素分析用于确定预后因素。使用Kaplan-Meier曲线和对数秩检验比较生存率。AKR 1B 10蛋白阳性表达率为58.5%，阴性表达率为41.5%。AKR 1B 10阳性胃癌样本的频率在有淋巴结转移的患者中增加，而在那些表现出肿瘤消退的患者中减少。AKR 1B 10阳性组的5年总生存率明显低于AKR 1B 10阴性组。AKR 1B 10表达与淋巴结转移和较差的预后相关，沿着对新辅助化疗的不良反应，表明AKR 1B 10可能是局部进展期胃癌治疗反应的潜在预测因子。
Effective methods for predicting tumor response to preoperative chemotherapy are required. Aldo-ketoreductase family 1 member B10 (AKR1B10) is predominantly expressed in the gastrointestinal tract and serves an important function in cancer development and progression. The present study investigated whether AKR1B10 expression may predict the therapeutic response of locally advanced gastric cancer. A total of 53 patients with gastric cancer underwent neoadjuvant chemotherapy followed by surgery between January 2006 and December 2015. The protein expression level of AKR1B10 was determined in paraffin-embedded biopsy specimens using immunohistochemistry. Western blotting confirmed that the AKR1B10 protein is primarily localized to the cytoplasm. χ2 and Fisher's exact tests were used to determine the association of AKR1B10 with a number of clinic opathological features. Univariate and multivariate analyses were used to identify the prognostic factors. Survival rates were compared using Kaplan-Meier curves with a log-rank test. The positive rate of AKR1B10 protein expression was 58.5%, whereas 41.5% samples exhibited negative expression. The frequency of AKR1B10-positive gastric cancer samples was increased in patients with lymph node metastasis and decreased in those exhibiting tumor regression. The 5-years overall survival rate for the AKR1B10-positive group was significantly poorer than that for the AKR1B10-negative group. AKR1B10 expression was associated with lymph node metastasis and a poorer prognosis, along with a poor response to neoadjuvant chemotherapy suggesting that AKR1B10 may be a potential predictor for the therapeutic response of locally-advanced gastric cancer.